

PHYTO NOVA

Sutherlandia SU1™ Tablets

SCHEDULING STATUS

S0

PROPRIETARY NAME (and dosage form)

Phyto Nova Sutherlandia SU1™ (tablets)

COMPOSITION

Each tablet contains:

Active ingredients:

300 mg milled select *Sutherlandia frutescens* SU1™

Inactive ingredients: Calcium phosphate dibasic dihydrate, magnesium stearate, sodium starch glycolate, vegetable cellulose, silicon dioxide, gum acacia.

PHARMACOLOGICAL CLASSIFICATION

Western Herbal

D.32.16 Other

PHARMACOLOGICAL ACTION

Sutherlandia frutescens SU1™ occurs naturally throughout the dry parts of southern Africa and has traditionally been used as a herbal medicine. One of the chemical constituents of *Sutherlandia*, L-canavanine, is an arginine analogue. L-canavanine has been reported to have anti-viral activity.

INDICATIONS

Phyto Nova Sutherlandia SU1™ may assist with immune system modulation.

CONTRAINDICATIONS

Not recommended for children under the age of 18 years.

WARNINGS AND SPECIAL PRECAUTIONS

Dizziness may rarely be experienced and can be prevented by taking Phyto Nova Sutherlandia SU1™ after meals. It is recommended that the use of the product be stopped two weeks before elective surgery.

INTERACTIONS

No known interactions.

Consult a doctor or other registered healthcare professional for advice on taking Phyto Nova Sutherlandia SU1™ if taking pharmaceutical medications for any illness.

Preliminary laboratory studies suggest there may be possible interactions with anti-retroviral medicines. There may be theoretical interactions with anti-hypertensive and anti-diabetic medication, requiring a possible reduction in the dose of these medications. Many common natural supplements (e.g. garlic, ginkgo, ginseng) may be implicated in prolonging bleeding time. This product should not be taken while on the anti-coagulants heparin and warfarin.

PREGNANCY AND LACTATION

Safety during pregnancy and breastfeeding has not been established.

DOSAGE AND DIRECTIONS FOR USE

Adults: Take one (1) tablet twice a day after meals.

Not recommended for children under the age of 18 years.

SIDE EFFECTS

Minor side effects may include occasional incidents of mild loose stool, mild constipation and dry mouth.

KNOWN SYMPTOMS OF OVERDOSAGE

None known

IDENTIFICATION

Pale green tablets with characteristic smell, weighing 500 mg each.

PRESENTATION

White plastic container with green screw cap, containing 60 tablets.

STORAGE INSTRUCTIONS

Store at or below 25 °C in a dry place.

KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER

To be allocated.

NAME AND ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION

Akacia™ Natural Medicines (Pty) Ltd

4 Brewery Street, Isando

Gauteng, 1609

DATE OF PUBLICATION OF PACKAGE INSERT

September 2011

This medicine has not been evaluated by the Medicines Control Council.
This medicine is not intended to diagnose, treat, cure or prevent any disease.

PHYTO NOVA

Sutherlandia SU1™ Tablette

SKEDULERINGSTATUS

S0

EIENDOMSNAAM (en doseervorm)

Phyto Nova Sutherlandia SU1™ (tablette)

SAMESTELLING

Elke tablet bevat:

Aktiewe bestanddele:

300 mg gemaalde uitgesoekte *Sutherlandia frutescens* SU1™

Onaktiewe bestanddele: Kalsiumfosfaat dibasiese dihidraat, magnesiumstearaat, natriumstyselgikolaat, plantaardige sellulose, silikondioksied, akasiagom.

FARMAKOLOGIESE KLASSIFIKASIE

Westerse Kruie

D.31.16 Ander

FARMAKOLOGIESE WERKING

Sutherlandia frutescens SU1™ is inheems aan die droë dele van Suider-Afrika en is tradisioneel as 'n kruidemidde gebruik. Een van die chemiese bestanddele van *Sutherlandia*, L-kanavanien, is 'n arginien-analoog. Dit is gerapporteer dat L-kanavanien anti-virale werking het.

INDIKASIES

Phyto Nova Sutherlandia SU1™ mag help om die immuunsisteem te moduleer.

KONTRA-INDIKASIES

Nie aanbeveel vir gebruik deur kinders jonger as 18 jaar nie.

WAARSKUWINGS EN SPESIALE VOORSORGMAATREËLS

Duiseligheid kan per geleentheid ervaar word en kan voorkom word deur Phyto Nova Sutherlandia SU1™ na etes te neem. Dit word aanbeveel dat die gebruik van Phyto Nova Sutherlandia SU1™ twee weke voor elektiewe chirurgie gestaak word.

INTERAKSIES

Geen interaksies bekend nie.

Konsulteer 'n dokter of professionele gesondheidsorgwerker vir advies rakende die gebruik van Phyto Nova Sutherlandia SU1™ indien farmaseutiese medikasies vir enige siekte geneem word. Voorlopige laboratoriumstudies wys daar mag moontlik interaksies met anti-retrovirale geneesmiddels wees. Daar mag teoreties interaksies wees met anti-hipertensiewe en anti-diabetiese medikasie wees, wat 'n verlaging in die dosis van hierdie medikasies kan nodig maak. Baie algemene natuurlike aanvullings (bv. knoffel, ginkgo, ginseng) mag moontlik bydra tot 'n verlenging van die bloedingstyd. Hierdie produk moet nie geneem word terwyl die antikoagulante heparien en warfarien gebruik word nie.

SWANGERSKAP EN BORSVOEDING

Veiligheid gedurende swangerskap en borsvoeding is nie bepaal nie.

DOSIS EN GEBRUIKSAANWYSINGS

Volwassenes: Neem een (1) tablet twee keer per dag na etes.

Nie aanbeveel vir kinders jonger as 18 jaar nie.

NEWE-EFFEKTE

Ligte newe-effekte sluit insidente van effense hardlywigheid, los stoelgange en droë mond per geleentheid in.

BEKENDE SIMPTOME VAN OORDOSERING

Geen bekend nie.

IDENTIFIKASIE

Liggroen tablette met 'n kenmerkende geur, wat 500 mg elk weeg.

AANBIEDING

Wit plastiekhouer met groen skroefprop, wat 60 tablette bevat.

BEWARINGSINSTRUKSIES

Bêre by of onder 25 °C, op 'n droë plek.

HOU BUITE BEREIK VAN KINDERS

REGISTRASIENOMMER

Sal toegeken word.

NAAM EN BESIGHEIDSADRES VAN DIE HOUEER VAN DIE REGISTRASIESERTIFIKAAT

Akacia™ Natural Medicines (Edms) Bpk

Brewerystraat 4, Isando

Gauteng, 1609

DATUM VAN PUBLIKASIE VAN DIE VOUBILJET

September 2011

Hierdie medisyne is nie deur die Medisynebeheerraad geëvalueer nie.

Hierdie medisyne is nie bedoel om enige siekte te diagnoseer, behandel, genees of voorkom.

Akacia™